<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-␤, misfolded proteins, predisposing genes, and aging</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Valerie</forename><surname>Askanas</surname></persName>
							<email>askanas@hsc.usc.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">USC Neuromuscular Center</orgName>
								<orgName type="institution" key="instit2">University of Southern California Keck School of Medicine</orgName>
								<orgName type="institution" key="instit3">Good Samaritan Hospital</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">USC Neuromuscular Center</orgName>
								<orgName type="institution" key="instit2">Good Samaritan Hospital</orgName>
								<address>
									<addrLine>637 South Lucas Avenue</addrLine>
									<postCode>90017-1912</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><surname>King Engel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">USC Neuromuscular Center</orgName>
								<orgName type="institution" key="instit2">University of Southern California Keck School of Medicine</orgName>
								<orgName type="institution" key="instit3">Good Samaritan Hospital</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-␤, misfolded proteins, predisposing genes, and aging</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">023C2CF3EE5C8AB2A002962CCB9C7919</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>sporadic inclusion-body myositis</term>
					<term>muscle fiber aging</term>
					<term>amyloid-␤</term>
					<term>misfolding of proteins ER endoplasmic reticulum h-IBM hereditary inclusion-body myopathies IBM inclusion-body myopathies s-IBM sporadic inclusion-body myositis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Purpose of review</head><p>Sporadic inclusion-body myositis, the most common muscle disease of older persons, is of unknown cause, and there is no successful treatment. Interest in sporadic inclusion-body myositis has been enhanced by the recent identification within the sporadic inclusion-body myositis muscle fibers of several abnormally accumulated proteins, which provides novel and important clues to the pathogenesis of sporadic inclusion-body myositis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recent findings</head><p>This article summarizes the most recent findings leading to better understanding of the players in the pathogenetic cascade. It is suggested that lymphocytic inflammatory component is probably secondary, and it may contribute only slightly to muscle fiber damage in sporadic inclusion-body myositis. However, it is proposed that the identified abnormal accumulation, aggregation, and misfolding of proteins, combined with and perhaps provoked by an aging intracellular milieu, more essentially lead to the vacuolar degeneration and atrophy of the muscle fibers that are specific to sporadic inclusion-body myositis. Abnormal accumulations of the amyloid-␤ precursor protein and of its proteolytic fragment, amyloid-␤, associated with the aging cellular muscle fiber environment, appear to be key pathogenic events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary</head><p>In conceptualizing a treatment for sporadic inclusion-body myositis, the accumulations of amyloid-␤42 and other unfolded proteins are now phenomena to be reckoned with. One would like to stop intracellular increase of the unfolded/misfolded proteins by reducing their formation and/or increasing their disposal. In addition, the identification of factors that would decrease intra-muscle fiber expressions of ␤-and ␥-secretases might lead to decreased production of putatively myotoxic oligomeric amyloid-␤42. Better understanding of the mechanisms and consequences of genes that predispose to sporadic inclusion-body myositis, and of human muscle fiber aging, could also provide new avenues toward the therapy of sporadic inclusion-body myositis. How to therapeutically capitalize on the new findings is now the challenge.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Sporadic inclusion-body myositis (s-IBM), the most common muscle disease of persons aged 50 years and older, is of unknown cause and unconfirmed pathogenesis <ref type="bibr">[1•-3•]</ref>. Its course is progressive, leading to severe disability. No consistently successful treatment is available. The clinical features of s-IBM and various treatment approaches were recently summarized <ref type="bibr">[1•-4]</ref>. This review focuses on the most recent research advances leading to our newest consideration to the s-IBM pathogenic cascade. We raise the novel possibility that, among other factors, the abnormal accumulation, aggregation, and misfolding of proteins, combined with and perhaps provoked by an aged intracellular milieu, leads to the s-IBM-specific vacuolar degeneration and muscle fiber atrophy. We emphasize that abnormal accumulations of the amyloid-␤ precursor protein and of its proteolytic fragment, amyloid-␤ (A␤), associated with the aging cellular muscle fiber environment, are key pathogenic events (Fig. <ref type="figure">1</ref>).</p><p>The term "hereditary inclusion-body myopathies" (h-IBM) was introduced in 1993 to designate hereditary muscle diseases with pathologic features strikingly resembling those of s-IBM except for lack of lymphocytic inflammation. Hence the term "myopathy" instead of "myositis" <ref type="bibr" target="#b7">[5]</ref>.</p><p>The h-IBMs are composed of several autosomal-recessive and autosomal-dominant syndromes of progressive muscle weakness with various clinical presentations. Even though several pathogenetic concepts apply both to s-IBM and the h-IBMs (Fig. <ref type="figure">1</ref>), the h-IBMs are not the subject of this review. They were recently reviewed <ref type="bibr">[6••]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General considerations</head><p>The diagnostic criteria of muscle biopsies of patients with s-IBM have recently been reviewed <ref type="bibr">[1•,2,7]</ref>. The main light microscopic features of the s-IBM muscle biopsy include (1) vacuolated muscle fibers, (2) intramuscle fiber amyloid inclusions, and (3) various degrees of lymphocytic cellular inflammation. Because of the presence of inflammation, s-IBM has been considered an inflammatory myopathy, together with polymyositis and dermatomyositis, and several recent reviews addressed the inflammatory aspects of these disorders <ref type="bibr">[8,9,10•]</ref>. Whereas in muscle biopsy specimens from s-IBM the inflammatory component is present, at least in the early involvement of a given muscle, patients with s-IBM as a group respond poorly to antidysimmune treatment, in contrast to patients with polymyositis and dermatomyo-sitis [1•-4,7-10•]. Patients over age 50 with what could be considered "pure PM" are rare <ref type="bibr">[1•</ref>]. Virtually all older patients with lymphocytic myositis have s-IBM. In s-IBM, lymphocytic inflammation may be a secondary component, occurring in response to "foreign" antigenic proteins (such as viral proteins or altered normal muscle proteins) abnormally produced within (see below) and "foreignizing" s-IBM muscle fibers, which can be antigen-presenting cells. Muscle fibers are known to induce antigen-specific immune responses and have recently been demonstrated to express B7.1/2-related costimulatory molecule ICOSL <ref type="bibr">[11•]</ref>. A possibility that excessive accumulation of A␤PP/A␤ induces inflammation has been proposed by us and by others [1•-3•,7,10•]. This possibility can be further supported by the finding of inflammation, in addition to other abnormalities, in transgenic mice muscle fibers overexpressing A␤ precursor protein (A␤PP) <ref type="bibr" target="#b15">[12,</ref><ref type="bibr" target="#b16">13]</ref>. Alternatively, non-muscle foreign protein, such as from a virus, may be produced in macrophages and be presented by them. Moreover, lymphocytic inflammation can occur in several human genetic muscle diseases that are generally considered noninflammatory, including dysferlin deficiency, laminin-2 deficiency, and facioscapular muscular dystrophy [14-</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1. Proposed pathogenetic cascade of sporadic inclusion-body myositis and the hereditary inclusion-body myopathies</head><p>In this model, sporadic inclusion-body myositis (s-IBM) is considered to be a multifactorial muscle disease associated with aging. It is proposed that various factors, including predisposing genes and possibly infectious agents and environmental factors, in association with aging, lead to key cellular mechanisms, presently unknown, that cause increased A␤PP transcription, resulting in A␤PP overexpression. That overexpression, with participation of factors causing abnormal A␤PP processing, leads to A␤42 &gt; A␤40 accumulation and oligomerization. Subsequently, the increased A␤, both partially aggregated (oligomerized) and fully aggregated (fibrillar, congophilic), leads to oxidative stress and several other abnormalities, resulting in muscle fiber degeneration, atrophy, and death. Those cellular abnormalities may be induced by A␤ acting either independently or in conjunction with oxidative stress and its effects.</p><p>16]. We have proposed that s-IBM is a multifactorial disease in which the milieu of the aged muscle fibers promotes development of the characteristic vacuolar degeneration and ectopic expression of several potentially toxic proteins, which lead to disease progression, independently of, and perhaps preceding, an inflammatory component <ref type="bibr">[1•</ref>]. Here we focus on the possible factors leading to the IBM-specific degenerative component of s-IBM muscle biopsy specimens.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Phenotypic similarities to Alzheimer disease brain</head><p>An intriguing feature of the s-IBM muscle fiber molecular phenotype is its similarity to the brain in Alzheimer disease (AD), including accumulations of amyloid-␤ precursor protein (A␤PP), amyloid-␤ (A␤), phosphorylated tau in the form of paired-helical filaments, presenilin-1, and several other "Alzheimer-characteristic" proteins <ref type="bibr">[1•,2,7</ref>]. Yet, each disease category, inclusion-body myositis (IBM) and AD, remains organ specific, involving postmitotic muscle fibers or postmitotic neurons. The tissue affected in the sporadic forms, muscle versus brain, may be influenced by ( <ref type="formula">1</ref>) an etiologic agent (possibly a virus), ( <ref type="formula">2</ref>) previous exposure to environmental factor(s), and/or (3) the patient's genetic background (the cellular microclimate), including different predisposing genes (see below).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Putative key pathogenic role of intracellular accumulation of A␤PP/A␤</head><p>We have proposed a key upstream or midstream role of increased intracellular A␤PP/A␤ in the pathogenesis of s-IBM, suggesting that it causes abnormal signal transduction, modulation of other genes, induction of oxidative stress, mitochondrial malfunction, and other abnormalities <ref type="bibr">[1•,2,7]</ref>. Our hypothesis is supported by the fact that accumulation of A␤PP/A␤ in s-IBM muscle fibers precedes other abnormalities and by our tissue culture studies showing that experimental overexpression of A␤PP through direct A␤PP gene transfer (via adenovirus vector) into normal, mature, cultured human muscle fibers induced several aspects of the IBM pathologic phenotype <ref type="bibr">[17]</ref><ref type="bibr">[18]</ref><ref type="bibr">[19]</ref>.</p><p>Additional support for our hypothesis of an intracellular toxicity of A␤PP and A␤ in the pathogenesis of IBM was provided by transgenic mouse models overexpressing A␤PP within muscle fibers, in which some aspects of the pathologic changes of IBM were produced, but only after the mice were aged <ref type="bibr" target="#b15">[12,</ref><ref type="bibr" target="#b16">13]</ref>. In AD, the pathogenic importance of an intracellular (intraneuronal) accumulation of A␤ was proposed by us previously <ref type="bibr">[20]</ref>, and it is beginning to gain favor in the AD field <ref type="bibr">[20]</ref><ref type="bibr" target="#b19">[21]</ref><ref type="bibr" target="#b20">[22]</ref><ref type="bibr" target="#b21">[23]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evidence of abnormalities of the A␤PP processing machinery</head><p>There is an increased evidence that some of the factors participating in the A␤PP processing are increased in S-IBM muscle fibers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACE1 and BACE2</head><p>BACE1 and BACE2, glycosylated transmembrane proteins, are recently discovered ␤-secretases that cleave A␤PP at the N terminal of A␤ <ref type="bibr" target="#b22">[24]</ref><ref type="bibr" target="#b23">[25]</ref><ref type="bibr" target="#b24">[26]</ref><ref type="bibr" target="#b25">[27]</ref>. Expression of BACE1 and BACE2 is increased in s-IBM muscle fibers, where they accumulate in the form of inclusions colocalizing with A␤ <ref type="bibr">[28,29••]</ref>. In addition, both BACEs coimmunoprecipitate with A␤PP in s-IBM muscle <ref type="bibr">(Vattemi and Askanas, unpublished observation, 2003)</ref>, providing novel evidence that they may participate in A␤PP processing and abnormal generation of A␤ there.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nicastrin and presenilins</head><p>␥-Secretase cleaves A␤PP at the C terminal of A␤, generating either A␤40 or A␤42 <ref type="bibr">[30••]</ref>. The nature of ␥-secretase is not known. However, nicastrin, in a complex with presenilin-1 and presenilin-2, is absolutely necessary for ␥-secretase action <ref type="bibr">[31•-33]</ref>. Nicastrin, Presenilin-1 and presenilin-2 are strongly overexpressed in s-IBM muscle fibers, where they colocalize with each other and with A␤ <ref type="bibr" target="#b34">[34,</ref><ref type="bibr" target="#b35">35]</ref>. They are physically associated with A␤PP in s-IBM and A␤PP-overexpressing muscle fibers <ref type="bibr">[Vattemi and Askanas, 2003,unpublished observations]</ref>. This strongly suggests that those factors participate in A␤ production within IBM muscle fibers. Our studies provided the first demonstration of nicastrin in human muscle, and they showed that together with BACE1, BACE2, and presenilins, IBM muscle fibers contain the machinery for A␤PP processing, leadingtogether with other factors (see below)-to abnormal A␤ production.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cholesterol and caveolin-1</head><p>Free cholesterol is abnormally accumulated in IBM muscle fibers <ref type="bibr">[36••]</ref>. It colocalizes with abnormally accumulated A␤, phosphorylated tau, and caveolin-1 <ref type="bibr">[36••,37]</ref>. In addition to being abnormally accumulated within s-IBM muscle fibers, caveolin-1, a major protein of plasmalemmal microdomain caveolae and an intracellular transporter of cholesterol <ref type="bibr" target="#b39">[38]</ref>, is physically associated with A␤PP in s-IBM muscle fibers, suggesting that it has a direct role in A␤PP processing <ref type="bibr">(Vattemi and Askanas, unpublished observations, 2003)</ref>. In nonmuscle cells, experimental loading with cholesterol increases A␤ production and amyloidogenesis <ref type="bibr">[36••]</ref>, and in A␤PP-overexpressing cultured human muscle fibers, exposure to cholesterol induces A␤ deposition and overexpression of caveolin-1 <ref type="bibr" target="#b40">[39]</ref>. We therefore propose that within s-IBM muscle fibers, cholesterol, instead of being properly metabolized or cleared, is deposited, with caveolin-1, at sites of A␤ accumulation and possibly at sites of A␤PP processing, where it may adversely increase A␤ production and induce A␤ misfolding and aggregation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cystatin C</head><p>Cystatin C, an endogenous cysteine protease inhibitor, was previously proposed to participate in A␤ deposition within the amyloid plaques of the brain in AD <ref type="bibr" target="#b41">[40,</ref><ref type="bibr" target="#b42">41]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pathogenetic cascade of inclusion-body myositis Askanas and Engel 739</head><p>Within muscle fiber biopsy specimens from s-IBM, cystatin C is strongly immunoreactive in the form of inclusions, which ultrastructurally colocalize with the A␤ immunoreactivity; its total expression is strongly increased; and it coimmunoprecipitates with A␤PP <ref type="bibr">[42••]</ref>. Our studies demonstrate for the first time, as far as we are aware, that cystatin C physically associates with A␤PP, suggesting that it possibly influences ABPP processing as well as A␤ deposition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A␤42 is preferentially accumulated in muscle fiber biopsy specimens from sporadic inclusion-body myositis</head><p>A␤ is a 40-42 amino acid peptide, whose toxicity is considerably enhanced by its self-association into toxic oligomers and into polymeric ␤-pleated sheet amyloid <ref type="bibr">[43,44••]</ref>. The more hydrophobic A␤42 is more prone to self-association and oligomerization, and it is much more cytotoxic than A␤40 <ref type="bibr" target="#b48">[45,</ref><ref type="bibr" target="#b49">46]</ref>. In s-IBM muscle fibers, deposits containing A␤42 are much more common than those containing A␤40 <ref type="bibr" target="#b50">[47]</ref>. All congophilic (fibrillar, amyloidic) A␤ inclusions contain A␤42, and some contain both A␤42 and A␤40 <ref type="bibr" target="#b50">[47]</ref>. By gold-immuno-electron microscopy, A␤42 is on 6-to 10-nm amyloid fibrils and amorphous material, whereas A␤40 is only on small patches of amorphous material but not on amyloid fibrils. If oligomerization of A␤42 is responsible for its toxicity and precedes its deposition into amyloid deposits, drugs preventing that oligomerization may offer a new treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evidence that unfolded/misfolded proteins may participate in pathogenesis of sporadic inclusion-body myositis</head><p>Several factors, or combination of factors, need to be considered. The two major types of intracellular inclusions in s-IBM muscle contain either A␤ or phosphorylated tau. By light microscopy, those containing A␤ are rounded and plaquelike, whereas those containing phosphorylated tau are more squiggly <ref type="bibr" target="#b9">[7]</ref>. Both types of inclusions are rich in ubiquitin, and they contain several other accumulated proteins, some of which are present in each type of the inclusion (Table1) <ref type="bibr">[1•,2,7]</ref>. Both forms of inclusions are "amyloid"-positive, indicating that they contain proteins in the fibrillar-␤-pleated sheet configuration <ref type="bibr" target="#b9">[7]</ref>. Some of the other proteins accumulated within the inclusions, such as ␣-synuclein, cellular prion protein, presenilin1, and SOD1, have, similarly to A␤ and tau, a propensity to unfold, misfold, and form ␤-pleated sheet amyloid <ref type="bibr" target="#b9">[7,</ref><ref type="bibr" target="#b34">34,</ref><ref type="bibr" target="#b57">[52]</ref><ref type="bibr" target="#b58">[53]</ref><ref type="bibr" target="#b59">[54]</ref><ref type="bibr" target="#b61">[55]</ref><ref type="bibr" target="#b73">66]</ref>. Accordingly, we postulate that the formation of the IBM-characteristic ubiquitinated multiprotein inclusions in s-IBM muscle is due to protein unfolding and misfolding . In general, protein aggregation leading to the formation of inclusions is considered to be caused by binding of partly unfolded or misfolded polypeptides induced by interaction among their inappropriately exposed hydrophobic surfaces [48 there is increased transcription of several genes, ie, A␤PP-751, cellular prion protein, enzymes involved in cellular defense against oxidative stress, and c-Jun <ref type="bibr">[1•,2,7]</ref>. Those factors may contribute to increased transcription, abnormal accumulation, and crowding of proteins, leading to their unfolding and possibly to abnormal glycosylation and other deleterious consequences to the proteins and the muscle cell.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Possible mechanisms underlying formation of inclusion bodies in muscle of inclusion-body myositis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diseases characterized by protein misfolding and aggregation are presently considered conformational diseases [48••]. Aggregations of proteins into insoluble intracellular protein complexes and inclusion bodies have been</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endoplasmic reticulum stress and unfolded protein response</head><p>The endoplasmic reticulum (ER) is an intracellular compartment having a critical role in the processing, folding and exporting of newly-synthesized proteins in the secretory pathway <ref type="bibr" target="#b65">[58,</ref><ref type="bibr" target="#b66">59]</ref>. Various factors, including the presence of misfolded proteins, oxidative stress, and abnormally glycosylated proteins, can interfere with ER function, leading to ER stress <ref type="bibr" target="#b67">[60]</ref><ref type="bibr" target="#b68">[61]</ref><ref type="bibr" target="#b69">[62]</ref> The unfolded protein response is a mechanism by which cells attempt to protect themselves against ER stress <ref type="bibr" target="#b67">[60,</ref><ref type="bibr" target="#b68">61]</ref>. It involves upregulation of several classes of ER chaperone proteins, whose main functions are to facilitate folding of the unfolded proteins and to prevent protein aggregation. In s-IBM muscle fibers, there are abnormal focal accumulations of five ER chaperones, BiP/GRP78, GRP94, Erp72, calreticulin and calnexin, each of which colocalizes with A␤ <ref type="bibr" target="#b70">[63]</ref>. Moreover, each of these five ER chaperones physically associates with A␤PP in s-IBM muscle <ref type="bibr">(Vattemi and Askanas, unpublished observations, 2003)</ref>, suggesting that they have a role in attempting to fold A␤PP and/or A␤. Accordingly, the ER stress and unfolded protein response in s-IBM muscle strongly suggest that unfolded/misfolded proteins participate in the pathogenic cascade.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transcription errors; accumulation of mutated ubiquitin</head><p>Ubiquitin (UBB +1 ) is produced by an acquired transcriptional error, a "molecular misreading," typically in an aging environment. The aberrant transcripts are formed as a result of dinucleotide loss during or after transcription and can be translated from the deletion onward into the +1 reading frame <ref type="bibr" target="#b71">[64,</ref><ref type="bibr" target="#b72">65]</ref>. UBB +1 was recently shown to be accumulated in AD brain <ref type="bibr" target="#b71">[64,</ref><ref type="bibr" target="#b72">65]</ref>. Aging and oxidative stress are possible facilitators of UBB +1 accumulation in AD brain. UBB +1 is toxic to cells because its ubiquitinated form inhibits proteasome <ref type="bibr">[66••]</ref>. Our most recent studies demonstrated an abnormal accumulation of UBB +1 in s-IBM muscle fibers, indicating for the first time, as far as we are aware, the important phenomenon of molecular misreading in diseased human muscle fibers <ref type="bibr" target="#b75">[67]</ref>. We therefore postulate that in IBM fibers, oxidative stress combined with the aging cellular environment leads to production of mutated UBB+, which may play a detrimental role in s-IBM pathogenesis by inhibiting proteasome function, leading to the accumulation of misfolded protein aggregations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Muscle fiber aging</head><p>s-IBM typically becomes clinically manifest after age 50, and more often in the 60s and 70s. Among patients with sporadic "inflammatory-myopathy" conditions, the above-described specific degenerative accumulations of proteins within muscle fibers occur only in s-IBM, not in polymyositis or dermatomyositis. We suggest that those accumulations are related to an aging-based degenerative pathogenic cascade.</p><p>For example, cellular aging was shown to promote the accumulation of abnormal proteins and to slow the degradation rate of normal and abnormal proteins [48••,49,51••]. The interrelated phenomena of agingrelated protein misfolding and aggregation of proteins may clarify the mechanisms relevant to s-IBM. In the cellular milieu of the aging muscle fiber, there may be diminished homeostatic mechanisms caused by either (1) diminished expression of "youthful" genes encoding beneficial cellular factors or (2) overexpression of yetunknown "aging" genes encoding toxic cellular factors. An association between aging and decreased protein sur- veillance was shown in a Caenorhabditis elegans model of polyglutamine disease in which mutation in the longevity gene "Age-1" exacerbated polyglutamine aggregation and toxicity <ref type="bibr" target="#b76">[68]</ref>. In addition, aging changes within muscle mitochondria <ref type="bibr" target="#b77">[69]</ref>, or elsewhere in the muscle fiber, may predispose to the mitochondrial abnormalities documented in s-IBM, potentially provoking a vicious circle between mitochondrial malfunctions and the oxidative stress demonstrated in the IBM fiber.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Putative role of predisposing genes</head><p>Predisposing genes may be important to S-IBM pathogenesis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transthyretin Val122Ile mutation predisposes to A␤ accumulation and oligomerization in cultured human muscle fibers</head><p>We previously postulated that susceptibility genes may play a role in the pathogenesis of s-IBM <ref type="bibr">[1•,2]</ref>. This could be exemplified by a patient with s-IBM and cardiac amyloidosis, associated with the Val122Ile transthyretin (TTR) mutation <ref type="bibr" target="#b78">[70]</ref>. Because wild TTR in vitro binds A␤ and prevents its fibrillar amyloidogenesis, we hypothesized that, conversely, mutant TTR may promote A␤ deposition and amyloidogenesis, thereby facilitating the development of IBM <ref type="bibr" target="#b78">[70]</ref>. Our newest studies in this patient's cultured muscle fibers show that his TTR Val122Ile mutation greatly exacerbated congophilia and A␤ accumulation and oligomerization, and it accelerated muscle fiber death <ref type="bibr">[71••]</ref>. Accordingly, TTR Val122Ile, or another mutation could be (1) a genetic predisposition factor for IBM, triggered by an aging cellular environment and/or other factors, or (2) increasing a preexisting propensity to have s-IBM and form intramuscle fiber A␤ deposits.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>We have presented the newest findings and approaches to the pathogenesis of s-IBM (Fig. <ref type="figure">1</ref>). These have not yet provided a definitive cause and treatment, but they have pointed to various new, potentially exciting avenues for exploring treatment approaches that could benefit patients with s-IBM. Examples are the identification of factors that would (1) decrease the intra-muscle fiber expressions of ␤and ␥-secretases that might lead to decreased production of toxic oligomeric A␤42 and (2) detoxify free radicals or prevent their formation within muscle fibers. Those measures might decrease the production of unfolded/misfolded proteins and their toxic consequences. A better understanding of the mechanisms and consequences of human muscle fiber aging may also provide new avenues for therapy in s-IBM.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>proposed to be importantly related to several neurodegenerative disorders, including AD, amyotrophic lateral sclerosis, Huntington disease, and Parkinson disease [49-51••]. Presently, little is known regarding the mechanisms preceding and leading to the formation of the inclusion bodies in s-IBM muscle. We proposed that the unfolding of proteins preceding their binding to each other and their final aggregation into inclusion bodies are responsible for cellular toxicity [1•].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>••-51••,57•]. Unfolding or misfolding of otherwise normal proteins can occur in vivo and in vitro under several circumstances, including macromolecular crowding, oxidative stress, exposure to toxins, and aging [48••-51••]. Markers of oxidative stress are increased in muscle fibers of s-IBM, and</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 . Protein composition of the A␤ and P-tau intracellular inclusions in s-IBM muscle fibers</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Pathogenetic cascade of inclusion-body myositis Askanas and Engel 741</cell></row><row><cell></cell><cell>A␤ inclusions</cell><cell>P-tau inclusions</cell></row><row><cell>Typical morphology</cell><cell></cell><cell></cell></row><row><cell>Light microscopy</cell><cell>Plaque-like, rounded;</cell><cell>Squiggly;</cell></row><row><cell>Electron microscopy</cell><cell>6-10nm filaments or</cell><cell>15-21nm paired-helical</cell></row><row><cell></cell><cell>amorphous material</cell><cell>filaments</cell></row><row><cell>Congophilia</cell><cell>+</cell><cell>+</cell></row><row><cell>Various proteins</cell><cell></cell><cell></cell></row><row><cell>A␤</cell><cell>+</cell><cell>−</cell></row><row><cell>N-and C-epitopes of A␤PP</cell><cell>+</cell><cell>−</cell></row><row><cell>Bace1 and Bace2</cell><cell>+</cell><cell>−</cell></row><row><cell>Cystatin C</cell><cell>+</cell><cell>−</cell></row><row><cell>␣-Synuclein</cell><cell>+</cell><cell>−</cell></row><row><cell>P-Tau</cell><cell>−</cell><cell>+</cell></row><row><cell>Ubiquitin</cell><cell>+</cell><cell>+</cell></row><row><cell>Nicastrin</cell><cell>+</cell><cell>+</cell></row><row><cell>Presenilin 1</cell><cell>+</cell><cell>+</cell></row><row><cell>Caveolin 1</cell><cell>+</cell><cell>+</cell></row><row><cell>Prion protein, cellular</cell><cell>+</cell><cell>+</cell></row><row><cell>Apolipoprotein E</cell><cell>+</cell><cell>+</cell></row><row><cell>UBB +1</cell><cell>+</cell><cell>+</cell></row><row><cell>ER chaperones</cell><cell></cell><cell></cell></row><row><cell>Calnexin</cell><cell>+</cell><cell>−</cell></row><row><cell>Calreticulin</cell><cell>+</cell><cell>−</cell></row><row><cell>GRP94</cell><cell>+</cell><cell>−</cell></row><row><cell>ERP72</cell><cell>+</cell><cell>−</cell></row><row><cell>BiP/GRP78</cell><cell>+</cell><cell>−</cell></row><row><cell>Signal transduction components</cell><cell></cell><cell></cell></row><row><cell>ERK</cell><cell>−</cell><cell>+</cell></row><row><cell>CDK5</cell><cell>−</cell><cell>+</cell></row><row><cell>Markers of oxidative stress</cell><cell></cell><cell></cell></row><row><cell>Nitrotyrosine</cell><cell>+</cell><cell>+</cell></row><row><cell>SOD1</cell><cell>+</cell><cell>+</cell></row><row><cell>Malondialdehyde</cell><cell>+</cell><cell>+</cell></row><row><cell>␣1-Antichymotrypsin</cell><cell>+</cell><cell>+</cell></row><row><cell>Transcription components</cell><cell></cell><cell></cell></row><row><cell>RNA Polymerase2</cell><cell>−</cell><cell>+</cell></row><row><cell>RNA</cell><cell>−</cell><cell>+</cell></row><row><cell>Survival-motor-neuron protein</cell><cell>−</cell><cell>+</cell></row><row><cell>c-Jun</cell><cell>+</cell><cell>+</cell></row><row><cell>NFB</cell><cell>+</cell><cell>+</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="16" xml:id="foot_0">Fitzsimmons RB: Facioscapulohumeral muscular dystrophy. Curr Opin Neurol 1999, 12:501-511.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="17" xml:id="foot_1">17 Askanas V, McFerrin J, Baque S, et al.: Transfer of ␤-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996, 93:1314-</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="18" xml:id="foot_2">1319. 18 Askanas V, McFerrin J, Alvarez RB, et al.: ␤APP gene transfer into cultured human muscle induces inclusion-body myositis aspects.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1997" xml:id="foot_3">Neuroreport 1997, 8:2155-2158. 19 McFerrin J, Engel WK, Askanas V: Impaired innervation of cultured human muscle overexpressing ␤APP experimentally and genetically: relevance to inclusion-body</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1998" xml:id="foot_4">myopathies. Neuroreport 1998, 9:3201-3205. 20 Askanas V, Engel WK: Does overexpression of ␤APP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion-body myositis, cultured human muscle and transgenic mice. Am J Pathol 1998, 153:1673-1677.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors thank their research and clinical colleagues and staff for their participation in various aspects of these studies.</p></div>
			</div>


			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Supported by the National Institutes of Health (NINDS grant NS34103 and NIA Merit Award AG16768), the Muscular Dystrophy Association, The Myositis Association, and the Helen Lewis and Sheldon Katz Research Funds.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">within the annual period of the review, have been highlighted as: • Of special interest</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Of outstanding interest</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="525" to="531" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Novel considerations regarding pathogenetic similarities of s-IBM and the H-IBM syndromes</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Newest pathogenetic considerations in inclusionbody myositis: possible role of amyloid-␤, cholesterol, relation to aging and to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rpts</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="427" to="433" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies: clinical, diagnostic and therapeutic aspects</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Extensive review of inflammatory myopathies</title>
				<imprint>
			<date type="published" when="2003">2003</date>
			<biblScope unit="page" from="407" to="425" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies: how to treat the difficult cases</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="99" to="101" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">New advances in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="732" to="741" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Hereditary inclusion-body myopathies. In The Molecular and Genetic Basis of Neurologic and Psychiatric disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Prusiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">An Imprint of Elsevier Science: Philadelphia</title>
		<imprint>
			<biblScope unit="page" from="501" to="509" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Newest considerations regarding the h-IBM syndromes</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The molecular and cellular pathology of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="300" to="306" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">New insights, current concepts in the pathophysiology of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunother</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="12" to="16" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Interesting review regarding immune aspects in s-IBM</title>
				<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="948" to="958" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitsdoerffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1026" to="1035" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Novel demonstration that muscle fibers have a machinery to serve as antigen presenting cells</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-s myopathy similar to human inclusion body myositis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hearn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Ogburn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1679" to="1686" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fukuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1687" to="1693" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rojas-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>De Luna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="2136" to="2138" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Partial laminin ␣2 chain deficiency in a patient with myopathy resembling inclusion-body myositis</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Blasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pareyson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="811" to="816" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Intraneuronal Abeta42 accumulation in human brain</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Gouras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Naslund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="15" to="20" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><surname>Glabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Neurosci</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="137" to="145" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Early intraneuronal A␤ deposition in the hippocampus of APP transgenic mice</title>
		<author>
			<persName><forename type="first">F-S</forename><surname>Shie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Leboeur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L-W</forename><surname>Jin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="123" to="129" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region</title>
		<author>
			<persName><forename type="first">F</forename><surname>Acquati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Accarino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">468</biblScope>
			<biblScope unit="page" from="59" to="64" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Expression analysis of BACE2 in brain and peripheral tissues</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Babu-Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Loeloff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="page" from="20647" to="20651" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Howlett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="609" to="619" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Purification and cloning of amyloid precursor protein beta-secretase from human brain</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barbour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">402</biblScope>
			<biblScope unit="page" from="537" to="540" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1962" to="1964" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">BACE1 and BACE2 in pathologic and normal human muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="page" from="150" to="158" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Detailed light microscopic and electron microscopic immunohistochemical and immunoblotting studies documenting the presence of BACE1 and BACE2 in normal and diseased human muscle fibers</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Alzheimer&apos;s disease: where do the presenilins fit in?</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sisodia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><surname>St</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Very interesting review regarding A␤PP processing and Alzheimer</title>
				<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="281" to="290" />
		</imprint>
	</monogr>
	<note>Hyslop PH: ␥-Secretase, Notch, A␤, and</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalsheker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1505" to="1535" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Reconstitution of gamma-secretase activity</title>
		<author>
			<persName><forename type="first">D</forename><surname>Edbauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Regula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Cell Biol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="486" to="488" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Novel studies regarding reconstitution of the ␥-secretase</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Nicastrin is required for assembly of presenilin/gammasecretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals</title>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="3272" to="3277" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Light and electron microscopic immunolocation of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="889" to="895" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Nicastrin, a novel protein participating in amyloid-␤ production, is overexpressed in sporadic inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">A315</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Jaworska-Wilczynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Wilczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="438" to="445" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">Important paper documenting that free cholesterol is abnormally accumulated in s-IBM muscle fibers</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Abnormal accumulation of caveolin-1 and its colocalization with cholesterol, amyloid-␤ and phosphorylated tau in inclusion-body myositis (IBM) muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A391</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Cholesterol and caveolae: structural and functional relationships</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Fielding</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1529</biblScope>
			<biblScope unit="page" from="210" to="222" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Combined influence of amyloid-␤ precursor protein (A␤PP) gene transfer and cholesterol excess on cultured normal human muscle fibers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Leclerc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A489</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Elevation of cystatin C in susceptible neurons in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Irizarry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Nitsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="1061" to="1068" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Codeposition of cystatin C with amyloidbeta protein in the brain of Alzheimer-disease patients</title>
		<author>
			<persName><forename type="first">E</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sastre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="94" to="104" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Cystatin C colocalizes with amyloid-␤ and co-immunoprecipitates with amyloid-␤ precursor protein in sporadic inclusion-body myositis muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1539" to="1546" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">Novel demonstration that cystatin C is abnormally accumulated in s-IBM muscle fibers and that it coimmunoprecipitates with A␤PP</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Diffusible, nonfibrillar ligands derived from A␤ 1-42 are potent central nervous system neurotoxins</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Barlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Chromy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="6448" to="6453" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">ADDLs and protofibrils: the missing links?</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="231" to="233" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Very important summary stressing the significance of the A␤ oligomers and protofibrils toxicity</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Naturally secreted oligomers of amyloid ␤ protein potently inhibit hippocampal long-term potentiation in vivo</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Klyubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Fadeeva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">416</biblScope>
			<biblScope unit="page" from="535" to="539" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Dahlgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Manelli</surname></persName>
		</author>
		<author>
			<persName><surname>Stine Wb Jr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="32046" to="32053" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Amyloid-␤42 is preferentially deposited in muscle biopsies of patients with sporadic inclusion-body myositis (s-IBM)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Checler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="333" to="334" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Hassles with taking out the garbage: aggravating aggresomes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Garcia-Mata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sztul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Traffic</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="388" to="396" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Excellent review regarding aggresome and unfolded proteins</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="15" to="32" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Danger: misfolding proteins</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tjt</forename><surname>Pinheiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">416</biblScope>
			<biblScope unit="page" from="483" to="484" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration</title>
		<author>
			<persName><forename type="first">Shoesmith</forename><surname>Berke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Paulson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Genet Dev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="253" to="261" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">Excellent review regarding the contribution of the unfolded proteins in various neurodegenerative disorders</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Novel immunolocalization of ␣-synuclei in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="592" to="598" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Prion protein is abnormally accumulated in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="25" to="28" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Characterization of cytoplasmic ␣-synuclein aggregates</title>
		<author>
			<persName><forename type="first">H-J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="48976" to="48983" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<title level="m" type="main">Detailed identification of ␣-synuclein aggregates</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wollmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lindquist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page" from="1781" to="1785" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Presenilin-binding protein forms aggresomes in monkey kidney COS-7 cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Namekata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="819" to="827" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Role of molecular chaperones in inclusion body formation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Carrió</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villaverde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">537</biblScope>
			<biblScope unit="page" from="215" to="221" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<monogr>
		<title level="m" type="main">Good description of the importance of the molecular chaperones in inclusion body formation</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">ER quality control: towards an understanding at the molecular level</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ellgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Helenius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Cell Biol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="431" to="437" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kaufman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1211" to="1233" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">The glucose-regulated proteins: stress induction and clinical applications</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Biochem Sci</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="504" to="510" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Tripartite management of unfolded proteins in the endoplasmic reticulum</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="451" to="454" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Orchestrating the unfolded protein response in health and disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kaufman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1389" to="1398" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Evidence of endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis (IBM) muscle</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A491</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Frameshift mutants of ␤-amyloid precursor protein and ubiquitin-␤ in Alzheimer&apos;s and Down patients</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>De Kleijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Van Den Hurk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="page" from="242" to="247" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Molecular misreading: a new type of transcript mutation expressed during aging</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kamel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1879" to="1891" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lindsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fms</forename><surname>De Vrij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lgc</forename><surname>Verhoef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="417" to="427" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title level="m" type="main">Pathogenetic cascade of inclusion-body myositis Askanas and Engel 743 Very important study showing that mutant ubiquitin, UBB +1 , substantially inhibits proteasomal protein degradation</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Accumulation of mutant UBB (UBB+1) in muscle fibers implicates a novel mechanism of molecular misreading in the pathogenesis of inclusion-body myositis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fratta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>in press</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">The threshold for polyglutamineexpansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Brignull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Weyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="10417" to="10422" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Michikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mallidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="4022" to="4027" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis, blood vessel and cardiac amyloidosis, and transthyretin Val122IIe allele</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="544" to="549" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Transthyretin Val122lle, accumulated A␤, and inclusion-body myositis aspects in cultured muscle</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="257" to="260" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<title level="m" type="main">First identification that mutated transthyretin promotes A␤ accumulation and IBM aspects in human muscle, providing a novel suggestion that mutated transthyretin may be a predisposing gene to IBM</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
